Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 16:12:620340.
doi: 10.3389/fphar.2021.620340. eCollection 2021.

The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies

Anji Xiong  1   2 , Deng Liu  1 , Huini Chen  1 , Guancui Yang  1 , Chen Xiong  1 , Yu Shuai  1 , Linqian He  1 , Zepeng Guo  1 , Liangwen Zhang  1 , Yuan Yang  3 , Beibei Cui  4 , Shiquan Shuai  1   2
Affiliations
Review

The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies

Anji Xiong et al. Front Pharmacol. .

Abstract

Background: Although infliximab has been recommended for the second-line treatment of seronegative spondyloarthropathy- or juvenile idiopathic arthritis-related uveitis, the issue of its systemic efficacy and safety in a broader diversity of refractory noninfectious uveitis is debatable. To assess the short-term and relatively long-term efficacy of infliximab in refractory noninfectious uveitis, we performed a systematic review and meta-analysis of observational studies. Methods: PubMed, Cochrane Library, EMBASE, and Wanfang Med Online were systematically searched from January 2005 to March 2020. Two investigators independently assessed eligibility. Data were independently collected by two investigators. The pooled proportions were estimated with patients for intraocular inflammation control and improvement of visual acuity. Pooled proportions with 95% credible intervals were computed. Study homogeneity was investigated using I 2 statistics to quantify the percentage of variation across studies. To pool the results, the Mantel-Haenszel fixed-effects or random-effects models were used. Results: Of 2316 studies identified, 16 unique studies with 509 unique participants were included in the meta-analysis. The pooled proportions of intraocular inflammation control reached 92% (95% CI: 87%-98%; I 2: 1%; p=0.42) and 95% (95% CI: 93%-97%; I 2: 0%; p=0.91) in groups of ≤6- and ≥12-month follow-up durations. During the relatively long follow-up period, the pooled proportions of maintaining visual acuity stable or increasing at least one line reached 99% (95% CI: 96%-100%; I 2: 0%; p=0.54) in the involved eyes. The corticosteroid-sparing effect of infliximab was also well demonstrated, with the proportion of corticosteroid-sparing success reaching 85.5% (112/131). Besides, about serious adverse events, 2.6% (13/500) of patients experienced hypersensitivity reactions, 2.4% (12/500) of patients experienced serious infections, 1.8% (9/500) of patients experienced autoimmune diseases, and 0.6% (3/500) of patients experienced neoplasia. Conclusions: This meta-analysis provided evidence that infliximab might be a promising choice in controlling inflammatory activity, gaining visual acuity, and sparing corticosteroid use with relatively few side effects when applied in treating refractory noninfectious uveitis. Systematic Review Registration: [website], identifier [registration number].

Keywords: anti-TNF-α; infliximab; noninfectious uveitis; refractory; uveitis treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart demonstrating the process of study selection.
FIGURE 2
FIGURE 2
Risk-of-bias summary of included studies using the AHRQ risk-of-bias tool.
FIGURE 3
FIGURE 3
Pooled proportion of controlled intraocular inflammation with a follow-up duration of ≤6 months.
FIGURE 4
FIGURE 4
Pooled proportion of controlled intraocular inflammation with a follow-up duration of ≥12 months.
FIGURE 5
FIGURE 5
Pooled proportion of controlled VA based on the affected eye with a follow-up duration of ≥12 months.
FIGURE 6
FIGURE 6
Pooled proportion of maintained VA stable or increased at least one line based on the affected eye with a follow-up duration of ≥12 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Angeles-Han S. T., Ringold S., Beukelman T., Lovell D., Cuello C. A., Becker M. L., et al. (2019). 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 71, 864–877. 10.1002/acr.2387110.1002/art.40885 - DOI - PMC - PubMed
    1. de Parisot A., Kodjikian L., Errera M.-H., Sedira N., Heron E., Pérard L., et al. (2017). Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). Am. J. Ophthalmol. 178, 176–185. 10.1016/j.ajo.2017.03.029 - DOI - PubMed
    1. de Smet M. D., Taylor S. R. J., Bodaghi B., Miserocchi E., Murray P. I., Pleyer U., et al. (2011). Understanding Uveitis: the Impact of Research on Visual Outcomes. Prog. Retin. Eye Res. 30, 452–470. 10.1016/j.preteyeres.2011.06.005 - DOI - PubMed
    1. Duica I., Voinea L.-M., Mitulescu C., Istrate S., Coman I.-C., Ciuluvica R. (2018). The Use of Biologic Therapies in Uveitis. rjo 61, 105–113. 10.22336/rjo.2018.16 - DOI - PMC - PubMed
    1. Giardina A., Ferrante A., Ciccia F., Vadalà M., Giardina E., Triolo G. (2011). One Year Study of Efficacy and Safety of Infliximab in the Treatment of Patients with Ocular and Neurological Behçet's Disease Refractory to Standard Immunosuppressive Drugs. Rheumatol. Int. 31, 33–37. 10.1007/s00296-009-1213-z - DOI - PubMed

LinkOut - more resources